Qianjiang Yongan Pharmaceutical Co Ltd - Asset Resilience Ratio
Qianjiang Yongan Pharmaceutical Co Ltd (002365) has an Asset Resilience Ratio of 30.38% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Qianjiang Yongan Pharmaceutical Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Qianjiang Yongan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Qianjiang Yongan Pharmaceutical Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Qianjiang Yongan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Qianjiang Yongan Pharmaceutical Co Ltd (002365) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥687.31 Million | 30.38% |
| Total Liquid Assets | CN¥687.31 Million | 30.38% |
Asset Resilience Insights
- Very High Liquidity: Qianjiang Yongan Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 30.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Qianjiang Yongan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Qianjiang Yongan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Qianjiang Yongan Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Qianjiang Yongan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.00% | CN¥600.16 Million ≈ $87.82 Million |
CN¥2.31 Billion ≈ $337.82 Million |
-0.85pp |
| 2023-12-31 | 26.85% | CN¥630.10 Million ≈ $92.20 Million |
CN¥2.35 Billion ≈ $343.46 Million |
+3.85pp |
| 2022-12-31 | 23.00% | CN¥557.50 Million ≈ $81.58 Million |
CN¥2.42 Billion ≈ $354.73 Million |
+3.14pp |
| 2021-12-31 | 19.86% | CN¥454.02 Million ≈ $66.44 Million |
CN¥2.29 Billion ≈ $334.50 Million |
-9.44pp |
| 2020-12-31 | 29.31% | CN¥634.10 Million ≈ $92.79 Million |
CN¥2.16 Billion ≈ $316.62 Million |
+9.14pp |
| 2019-12-31 | 20.16% | CN¥384.71 Million ≈ $56.29 Million |
CN¥1.91 Billion ≈ $279.18 Million |
+18.37pp |
| 2018-12-31 | 1.80% | CN¥34.70 Million ≈ $5.08 Million |
CN¥1.93 Billion ≈ $282.28 Million |
+0.70pp |
| 2017-12-31 | 1.10% | CN¥17.33 Million ≈ $2.54 Million |
CN¥1.58 Billion ≈ $231.19 Million |
-0.19pp |
| 2016-12-31 | 1.28% | CN¥16.33 Million ≈ $2.39 Million |
CN¥1.27 Billion ≈ $186.33 Million |
-23.07pp |
| 2015-12-31 | 24.36% | CN¥293.00 Million ≈ $42.88 Million |
CN¥1.20 Billion ≈ $176.04 Million |
+0.85pp |
| 2014-12-31 | 23.50% | CN¥279.00 Million ≈ $40.83 Million |
CN¥1.19 Billion ≈ $173.70 Million |
-- |
About Qianjiang Yongan Pharmaceutical Co Ltd
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmace… Read more